Loading patent…
AssigneeIncellDx, Inc.
InventorsBruce K. Patterson, Amanda Noel Chargin, Keith Shults
Estimating the term…
Methods are provided for assaying neoplastic cells and/or neoplasia-related cells. Aspects of the methods involve de-tecting heterogeneity, per cell programmed-death ligand 1 (PD-L1) expression, and/or proliferation of neoplasia and/or neoplasia-re-lated cells. Aspects of the methods include cytometrically assaying a labeled cell suspension to quantify per cell heterogeneity, per cell PD-L1 expression, proliferation, and/or other parameters to detect whether a neoplastic cell is present in the neoplasia sample. Aspects of the provided methods also include treating a subject based on the outcome of such an assay. In addition, kits that find use in practicing the subject methods are also provided.
A method of detecting whether a neoplastic cell having a heterogeneity index above a predetermined threshold is present in a neoplasia sample, the method comprising:
The method according to any of the preceding claims, wherein the detected cell is proliferative.
The method according to any of the preceding claims, wherein the labeling further comprises contacting the neoplasia sample with at least one labeled binding member specific for immune cells.
The method according to any of the preceding claims, wherein the detected cell is a circulating tumor cell, a hematopoietic cancer cell, or a cell of a solid tumor.
The method according to any of the preceding claims, wherein the predetermined threshold comprises a cell complexity threshold, a DNA content threshold, and a PD-L1 threshold of 100 or more PD-L1 molecules per cell.
A method of indirectly detecting whether circulating tumor cells (CTCs) are present in a subject having a neoplasia, the method comprising:
Dependencies are inferred from the claim text.